Stay updated on Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial
Sign up to get notified when there's something new on the Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial page.

Latest updates to the Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.3%
- Check9 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
- Check16 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference5%
- Check23 days agoNo Change Detected
- Check45 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check59 days agoChange DetectedThe web page has been updated to version 2.15.0, replacing the previous version 2.14.4.SummaryDifference1.0%
- Check67 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
Stay in the know with updates to Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial page.